Pfizer Inc. Stock
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | -0.210% | 0.086% | 0.474% | -1.955% | 9.610% | -37.500% | -20.120% |
| Johnson & Johnson | 0.360% | 1.907% | 2.976% | 40.565% | 19.441% | 46.191% | 58.222% |
| AbbVie Inc. | -1.740% | -2.725% | -1.128% | -1.118% | -1.833% | 36.216% | 113.086% |
| BioMarin Pharmaceutical Inc. | -0.160% | -2.735% | 1.546% | -21.321% | 0.629% | -38.980% | -20.181% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of Pfizer Inc. (PFE), a major player within the pharmaceuticals industry, a mixed picture starts to emerge. On the one hand, the company boasts a solid revenue stream and demonstrates a commendable operating margin, creating an impression of profitability. On the other hand, several warning signs appear in the form of declining growth metrics and concerns over income stability. Now, let’s break down the analysis into pros and cons to provide a comprehensive view.
Strong Revenue Performance: Pfizer reported a total revenue of approximately $54.89 billion over the trailing twelve months. This figure suggests that the company has maintained a robust sales figure, driven largely by their pharmaceutical portfolio, including well-known products and newly developed vaccines.
Healthy Operating Margins: The operating margin, standing at around 31.63%, illustrates the company's efficiency in turning sales into profit. This is relatively strong for the pharmaceutical sector, indicating that Pfizer is effectively managing its operating expenses relative to its revenue.
Comments
News
1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
The wash-out from the COVID-19 pandemic has been brutal for any pharmaceutical stock. Pfizer (NYSE: PFE) has been no exception. As a vaccine maker, Pfizer has faced headwinds to growth in the last
2 Healthcare Stocks That Are Too Cheap to Ignore
Some indicators suggest that equity markets are currently overvalued. For instance, the S&P 500 Shiller CAPE ratio is near multi-year highs. In this environment, it pays to look for bargains, stocks
Pfizer's Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable?
A key ratio for dividend investors when looking at dividend stocks is the payout ratio. Since it tells you how large the dividend is with respect to earnings, it can be a good gauge of whether or